Search: id:"swepub:oai:DiVA.org:umu-25669" >
Vandetanib alters t...
-
Wibom, Carl,1977-Umeå universitet,Onkologi
(author)
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model
- Article/chapterEnglish2010
Publisher, publication year, extent ...
-
Spandidos Publications,2010
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:umu-25669
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-25669URI
-
https://doi.org/10.3892/ijo_00000739DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
The treatment of glioblastoma is unsatisfactory. Improved understanding of the biological effects of treatment, together with development of new tools to predict outcome of the initiated treatment are therefore of great need. Vandetanib (ZD6474) is mainly a vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor. This study investigated the pattern of protein expression in brain tumor and normal brain tissue, following treatment with vandetanib in a rat glioma model. BT4C-cells were stereotactically implanted into the brain of BD IX rats. The rats were divided into three different experiments. The treatment schedule for experiments one and two consisted of daily, oral doses of vandetanib from day 6 until day 12 or 20 after implantation, respectively. In the third experiment, each animal received a single dose of vandetanib on day 19 after implantation and was then sacrificed 2, 8 or 24 h thereafter. The protein expression profiles were analyzed by SELDI-TOF-MS and evaluated with multivariate statistical methods. Following treatment with vandetanib, we found significantly altered protein expression pattern in malignant glioma and normal brain. Analyzing protein spectra is an interesting option to assess biological effects induced in brain tissue by signal transduction inhibitors such as vandetanib.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sandström, MariaUmeå universitet,Onkologi(Swepub:umu)maalin96
(author)
-
Henriksson, RogerUmeå universitet,Onkologi(Swepub:umu)rohe0003
(author)
-
Antti, HenrikUmeå universitet,Kemiska institutionen(Swepub:umu)hean0004
(author)
-
Johansson, MikaelUmeå universitet,Onkologi(Swepub:umu)mijo0025
(author)
-
Bergenheim, A TommyUmeå universitet,Neurokirurgi(Swepub:umu)tobe0004
(author)
-
Umeå universitetOnkologi
(creator_code:org_t)
Related titles
-
In:International Journal of Cancer: Spandidos Publications37:4, s. 879-8900020-71361097-02151019-64391791-2423
Internet link
Find in a library
To the university's database